Replimune Group Inc to Host Virtual Investor Event Transcript
Good morning, and thank you for joining our investor conference call. We're excited to have this opportunity to share with everyone our first data set from a study being run with the registrational intent.
Before we begin, I need to highlight our forward-looking statement. On Slide 3, I'm Philip Astley-Sparke, CEO of Replimune. And I have with me today from management Robert Coffin, our President and Chief R&D Officer; and Sushil Patel, our Chief Commercial Officer.
We're also very pleased to have with us today several leading physicians from sites, all with considerable experience of using our products. Dr. Mark Middleton, PI on the IGNYTE study, for which we are reporting data today. Mark is Professor of Experimental Cancer Medicine and Consultant Medical Oncologist at the Oxford Cancer Centre and Head of the Department of Oncology at the University of Oxford.
Dr. Mike Wong, Professor in the Department of Melanoma Medical Oncology at MD Anderson. And Dr. Kevin Harrington, Professor in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
